suggests that BCAA administration might
be a viable way of attenuating dopa
minergic overactivity in pathological states.
It is of additional interest that in this
study the control drink was a true placebo.
Our original study employed a ‘balanced’
drink containing substantial doses of tyro
sine, making it possible that the difference
in effects simply reflected a contrast